155 related articles for article (PubMed ID: 30962674)
21. Povidone iodine for the treatment of adenoviral conjunctivitis.
Dang RM; Watt K; Hui A
Clin Exp Optom; 2021 Apr; 104(3):308-314. PubMed ID: 33689609
[TBL] [Abstract][Full Text] [Related]
22. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis.
Pepose JS; Ahuja A; Liu W; Narvekar A; Haque R
Am J Ophthalmol; 2019 Sep; 205():197. PubMed ID: 31327463
[No Abstract] [Full Text] [Related]
23. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for the Treatment of Adenoviral Conjunctivitis.
Ramakrishnan S; Vempati J; Baskaran P
Am J Ophthalmol; 2019 Aug; 204():140. PubMed ID: 31235065
[No Abstract] [Full Text] [Related]
24. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis.
Cinal A
Am J Ophthalmol; 2019 Jan; 197():184. PubMed ID: 30389099
[No Abstract] [Full Text] [Related]
25. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
26. Success of Masking 5% Povidone-Iodine Treatment: The Reducing Adenoviral Patient Infected Days Study.
Whiteside MM; Shorter ES; Margolis MS; Alvi F; Huecker JB; Than TP; Migneco MK; Harthan JS; Morettin CE; Hartwick ATE; Johnson SD; Perera CD; Gordon MO
Optom Vis Sci; 2021 May; 98(5):469-475. PubMed ID: 33973917
[TBL] [Abstract][Full Text] [Related]
27. Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials.
Wirta DL; Korenfeld MS; Foster S; Smyth-Medina R; Bacharach J; Kannarr SR; Jaros MJ; Slonim CB
Clin Ophthalmol; 2021; 15():4035-4048. PubMed ID: 34675472
[TBL] [Abstract][Full Text] [Related]
28. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
Chang MH; Fung HB
Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
[TBL] [Abstract][Full Text] [Related]
29. A controlled trial of povidone-iodine to treat infectious conjunctivitis in children.
Isenberg SJ; Apt L; Valenton M; Del Signore M; Cubillan L; Labrador MA; Chan P; Berman NG
Am J Ophthalmol; 2002 Nov; 134(5):681-8. PubMed ID: 12429243
[TBL] [Abstract][Full Text] [Related]
30. Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.
Sanfilippo CM; Allaire CM; DeCory HH
Drugs R D; 2017 Mar; 17(1):167-175. PubMed ID: 28078599
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
[TBL] [Abstract][Full Text] [Related]
32. The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis.
Starr CE; Nichols KK; Lang JR; Brady TC
Clin Ophthalmol; 2023; 17():3867-3875. PubMed ID: 38105911
[TBL] [Abstract][Full Text] [Related]
33. Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis.
Clement C; Capriotti JA; Kumar M; Hobden JA; Foster TP; Bhattacharjee PS; Thompson HW; Mahmud R; Liang B; Hill JM
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):339-44. PubMed ID: 20702820
[TBL] [Abstract][Full Text] [Related]
34. A systematic review and meta-analysis on the efficacy of topical povidone iodine in adenoviral conjunctivitis.
González Martín-Moro J; Zarallo-Gallardo J; Guzmán-Almagro E; Antón Rodríguez C
Cont Lens Anterior Eye; 2023 Oct; 46(5):101873. PubMed ID: 37380515
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
Berdy GJ; Stoppel JO; Epstein AB
Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
[TBL] [Abstract][Full Text] [Related]
36. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
Gong L; Sun X; Qu J; Wang L; Zhang M; Zhang H; Wang L; Gu Y; Elion-Mboussa A; Roy L; Zhu B
Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
[TBL] [Abstract][Full Text] [Related]
37. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections.
Silverstein BE; Morris TW; Gearinger LS; Decory HH; Comstock TL
Clin Ophthalmol; 2012; 6():1987-96. PubMed ID: 23233796
[TBL] [Abstract][Full Text] [Related]
38. Vehicle-Controlled, Phase 2 Clinical Trial of a Sustained-Release Dexamethasone Intracanalicular Insert in a Chronic Allergen Challenge Model.
Torkildsen G; Abelson MB; Gomes PJ; McLaurin E; Potts SL; Mah FS
J Ocul Pharmacol Ther; 2017 Mar; 33(2):79-90. PubMed ID: 28072552
[TBL] [Abstract][Full Text] [Related]
39. Comment on: A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis.
Kanclerz P; Myers WG
Am J Ophthalmol; 2020 Oct; 218():353. PubMed ID: 32826035
[No Abstract] [Full Text] [Related]
40. Reply to Comment on: A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis.
Ta CN; Raizman MB; Gross RD; Joshi S; Mallick S; Wang Y; Segal B
Am J Ophthalmol; 2020 Oct; 218():354. PubMed ID: 32826036
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
